Emerging monoclonal antibody therapies for malignant gliomas

David E. Gerber, John Laterra

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

An improved understanding of the molecular characteristics of gliomas has led to the recognition of potential antigen targets and monoclonal antibody (mAb) therapies for these challenging tumors. The design of glioma mAbs - including species, construct, immunoglobulin isotype and conjugate - affects their delivery, efficacy and toxicities. mAbs that are under study for glioma therapy include some mAbs that are currently approved for use in the treatment of other cancers, as well as novel molecules. Although the greatest experience so far is with locally administered, radiolabeled mAbs, systemic unconjugated mAbs are being studied increasingly for glioma treatment. Previous experience with mAbs in other malignancies may provide guidance for their use in the treatment of CNS malignancies.

Original languageEnglish (US)
Pages (from-to)477-494
Number of pages18
JournalExpert Opinion on Investigational Drugs
Volume16
Issue number4
DOIs
StatePublished - Apr 2007

Fingerprint

Glioma
Monoclonal Antibodies
Neoplasms
Immunoglobulin Isotypes
Therapeutics
Antigens

Keywords

  • Antibody-dependent cellular cytotoxicity
  • Blood-brain barrier
  • Brain tumor
  • Glioma
  • Monoclonal antibody
  • Radioisotope
  • Receptor tyrosine kinase
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmacology

Cite this

Emerging monoclonal antibody therapies for malignant gliomas. / Gerber, David E.; Laterra, John.

In: Expert Opinion on Investigational Drugs, Vol. 16, No. 4, 04.2007, p. 477-494.

Research output: Contribution to journalArticle

@article{3405653fa90e44fa99b4e8f8337c163f,
title = "Emerging monoclonal antibody therapies for malignant gliomas",
abstract = "An improved understanding of the molecular characteristics of gliomas has led to the recognition of potential antigen targets and monoclonal antibody (mAb) therapies for these challenging tumors. The design of glioma mAbs - including species, construct, immunoglobulin isotype and conjugate - affects their delivery, efficacy and toxicities. mAbs that are under study for glioma therapy include some mAbs that are currently approved for use in the treatment of other cancers, as well as novel molecules. Although the greatest experience so far is with locally administered, radiolabeled mAbs, systemic unconjugated mAbs are being studied increasingly for glioma treatment. Previous experience with mAbs in other malignancies may provide guidance for their use in the treatment of CNS malignancies.",
keywords = "Antibody-dependent cellular cytotoxicity, Blood-brain barrier, Brain tumor, Glioma, Monoclonal antibody, Radioisotope, Receptor tyrosine kinase, Targeted therapy",
author = "Gerber, {David E.} and John Laterra",
year = "2007",
month = "4",
doi = "10.1517/13543784.16.4.477",
language = "English (US)",
volume = "16",
pages = "477--494",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Emerging monoclonal antibody therapies for malignant gliomas

AU - Gerber, David E.

AU - Laterra, John

PY - 2007/4

Y1 - 2007/4

N2 - An improved understanding of the molecular characteristics of gliomas has led to the recognition of potential antigen targets and monoclonal antibody (mAb) therapies for these challenging tumors. The design of glioma mAbs - including species, construct, immunoglobulin isotype and conjugate - affects their delivery, efficacy and toxicities. mAbs that are under study for glioma therapy include some mAbs that are currently approved for use in the treatment of other cancers, as well as novel molecules. Although the greatest experience so far is with locally administered, radiolabeled mAbs, systemic unconjugated mAbs are being studied increasingly for glioma treatment. Previous experience with mAbs in other malignancies may provide guidance for their use in the treatment of CNS malignancies.

AB - An improved understanding of the molecular characteristics of gliomas has led to the recognition of potential antigen targets and monoclonal antibody (mAb) therapies for these challenging tumors. The design of glioma mAbs - including species, construct, immunoglobulin isotype and conjugate - affects their delivery, efficacy and toxicities. mAbs that are under study for glioma therapy include some mAbs that are currently approved for use in the treatment of other cancers, as well as novel molecules. Although the greatest experience so far is with locally administered, radiolabeled mAbs, systemic unconjugated mAbs are being studied increasingly for glioma treatment. Previous experience with mAbs in other malignancies may provide guidance for their use in the treatment of CNS malignancies.

KW - Antibody-dependent cellular cytotoxicity

KW - Blood-brain barrier

KW - Brain tumor

KW - Glioma

KW - Monoclonal antibody

KW - Radioisotope

KW - Receptor tyrosine kinase

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=34147150749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147150749&partnerID=8YFLogxK

U2 - 10.1517/13543784.16.4.477

DO - 10.1517/13543784.16.4.477

M3 - Article

VL - 16

SP - 477

EP - 494

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 4

ER -